CAMBRIDGE, Mass., March 24 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that it will present at two
upcoming conferences on Thursday, March 31, 2005: Smith Barney Citigroup's
2005 Healthcare Conference being held March 29-31, 2005 in Washington, D.C.
and Lehman Brothers' Eighth Annual Healthcare Conference being held March 30-
April 1, 2005 in Miami, Florida.
Michael J. Astrue, President and Chief Executive Officer, will present an
overview of TKT's business activities and product pipeline at the Citigroup
conference on Thursday, March 31, 2005 at 10:20 a.m. Eastern Time.
David D. Pendergast, Ph.D., Executive Vice President and Chief Operating
Officer will present an overview of TKT's business activities and product
pipeline at the Lehman Brothers conference on Thursday, March 31, 2005 at 3:15
p.m. Eastern Time.
A live audio webcast of these presentations will be available at
http://www.tktx.com on TKT's Investor Information website under the Events
category. A replay will be available for approximately 30 days after the
webcast.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
South America. Additional information about TKT is available on the company's
website at http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA.
Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Senior Director,
Corporate Communications of TKT, +1-617-349-0271
|
